Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.
暂无分享,去创建一个
[1] B. Sands,et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2019, The New England journal of medicine.
[2] L. Peyrin-Biroulet,et al. Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. , 2019, Journal of Crohn's & colitis.
[3] J. Lindsay,et al. 800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve Study , 2019, Gastroenterology.
[4] S. Vermeire,et al. 1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis , 2019, Gastroenterology.
[5] N. Harpaz,et al. Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity , 2019, Gut.
[6] Siddharth Singh,et al. P081 HISTOLOGIC HEALING RATES OF MEDICAL THERAPIES FOR ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS , 2019, Inflammatory Bowel Diseases.
[7] L. Peyrin-Biroulet,et al. Effects of Ustekinumab Induction Therapy on Endoscopic and Histologic Healing in the UNIFI Phase 3 Study in Ulcerative Colitis , 2019, Zeitschrift für Gastroenterologie.
[8] S. Targan,et al. Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI , 2019, Zeitschrift für Gastroenterologie.
[9] G. D'Haens,et al. Definitions of response and remission for the Robarts Histopathology Index , 2018, Gut.
[10] B. Vaughn,et al. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease , 2018, Digestive Diseases and Sciences.
[11] A. Boruvka,et al. Tu2006 - Etrolizumab Induction Therapy Improves Histologic Outcomes in Anti-TNF-Failed Patients with Ulcerative Colitis: Results from the Hickory Open-Label Induction Cohort , 2018 .
[12] I. Nagtegaal,et al. Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion , 2018, Journal of Crohn's & Colitis.
[13] C. Taxonera,et al. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis , 2018, Digestive Diseases and Sciences.
[14] S. Vermeire,et al. Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study , 2018, United European gastroenterology journal.
[15] S. Ng,et al. Endoscopic and Histological Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia , 2017, Journal of Crohn's & colitis.
[16] I. Ojanguren,et al. Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[17] R. Pinho,et al. Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis , 2017, Inflammatory bowel diseases.
[18] A. O’Connor,et al. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. , 2017, Gastrointestinal endoscopy.
[19] S. Wong,et al. Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores , 2017, Journal of Crohn's & colitis.
[20] S. Necozione,et al. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine , 2017, Therapeutic advances in gastroenterology.
[21] L. Peyrin-Biroulet,et al. Ulcerative colitis , 2017, The Lancet.
[22] M. Keir,et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC , 2016, Gut.
[23] L. Laine,et al. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis , 2016, The American Journal of Gastroenterology.
[24] P. Rutgeerts,et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC , 2016, Gut.
[25] G. Macedo,et al. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. , 2016, Journal of Crohn's & colitis.
[26] S. Vermeire,et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. , 2016, The New England journal of medicine.
[27] A. Cheifetz,et al. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study , 2016, The American Journal of Gastroenterology.
[28] L. Stitt,et al. Development and validation of a histological index for UC , 2015, Gut.
[29] S. Travis,et al. Development and validation of the Nancy histological index for UC , 2015, Gut.
[30] L. Peyrin-Biroulet,et al. Review article: the histological assessment of disease activity in ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.
[31] G. D'Haens,et al. Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.
[32] T. Murdoch,et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.
[33] B. Warren,et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up , 2015, Gut.
[34] S. Travis,et al. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. , 2014, Journal of Crohn's & colitis.
[35] Michael Joseph Peterson,et al. Reproducibility of histological assessments of disease activity in UC , 2014, Gut.
[36] J. Salleron,et al. Comparing histological activity indexes in UC , 2014, Gut.
[37] B. Korelitz,et al. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. , 2014, World journal of gastroenterology.
[38] M. Vandervoort,et al. Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices , 2014, Inflammatory bowel diseases.
[39] S. Nordling,et al. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: A case–control observational study based on registry data , 2014, International journal of cancer.
[40] D. Rubin,et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[41] A. Griffiths,et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[42] A. Cheifetz,et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[43] A. Zinsmeister,et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[44] P. Rutgeerts,et al. Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing , 2012, The American Journal of Gastroenterology.
[45] J. Cotter,et al. Review of the disease course among adult ulcerative colitis population‐based longitudinal cohorts , 2012, Inflammatory bowel diseases.
[46] L. Gheorghe,et al. Endomicroscopy for assessing mucosal healing in patients with ulcerative colitis. , 2011, Journal of gastrointestinal and liver diseases : JGLD.
[47] D. Franchimont,et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. , 2011, Journal of Crohn's & colitis.
[48] B. Korelitz. Mucosal healing as an index of colitis activity: back to histological healing for future indices. , 2010, Inflammatory bowel diseases.
[49] Markus F. Neurath,et al. New pathophysiological insights and modern treatment of IBD , 2010, Journal of Gastroenterology.
[50] M. Thabane,et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.
[51] A. Griffiths,et al. Oral budesonide for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.
[52] S. Ng,et al. Therapeutic strategies for the management of ulcerative colitis , 2009, Inflammatory bowel diseases.
[53] I. Gorelov,et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.
[54] N. Harpaz,et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. , 2007, Gastroenterology.
[55] R. Petras,et al. Pathology of inflammatory bowel disease. , 2007, Seminars in pediatric surgery.
[56] S. Targan,et al. Inflammatory bowel disease diagnosis, evaluation and classification: state-of-the art approach , 2007, Current opinion in gastroenterology.
[57] Philippe Marteau,et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.
[58] P. Rutgeerts,et al. Infliximab Results in Reduction of Inflammation and Inflammatory Markers in the Mucosa of Ulcerative Colitis Patients: The ACT 1 Trial , 2005 .
[59] A. Cohen,et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.
[60] C. Fiocchi,et al. Adequacy of mucosal biopsies for evaluation of intestinal cytokine-specific mRNA , 1995, Digestive Diseases and Sciences.
[61] Alastair Forbes,et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.
[62] I. S. Shaw,et al. Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.
[63] A. Cohen,et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.
[64] A. Öst,et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.
[65] S. Riley,et al. Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.
[66] R. Willén,et al. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.
[67] B. Korelitz,et al. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. , 1975, The American journal of gastroenterology.
[68] A. Dick,et al. Persistence of mucosal abnormality in ulcerative colitis. , 1966, Gut.
[69] A. Dick,et al. Ulcerative Colitis , 1961 .
[70] S. Truelove,et al. Cortisone and Corticotrophin in Ulcerative Colitis , 1959, British medical journal.
[71] S. Truelove,et al. Biopsy Studies in Ulcerative Colitis , 1956, British medical journal.